Keck School Faculty

Dan Ruderman, PhD
Dan Ruderman, PhD
Assistant Professor of Research Medicine
Provost - Ellison Institute
CSC 2250 Biggy St. Ste. 240 Health Sciences Campus Los Angeles
Dan Ruderman received his doctorate in theoretical physics from the University of California at Berkeley, followed by postdoctoral research at Cambridge University, USC, and the Salk Institute. Dr. Ruderman continued his scientific research in the industrial setting, first in solid tumor target discovery through integrative genomics at Berlex Biosciences, and then in proteomic biomarker discovery at Applied Minds.

He was Founding Scientist at Applied Proteomics, a biomarker company spun out from Applied Minds in 2007. Dr. Ruderman joined CAMM in 2011, where his research focuses on signaling dynamics in cancer cells and systems biology interpretations of high-dimensional cancer assays, such as gene expression, proteomics, and autoantibodies.

Alfred E. Sloan Foundation: Postdoctoral Fellowship, 1996-1998

Sloan Foundation: Postdoctoral Fellowship, 1996-1998

National Science Foundation/ North Atlantic Treaty Organization: Postdoctoral Fellowship, 1994

National Science Foundation: Fellowship, 1993

Fannie and John Hertz Foundation : Fellowship, 1989-1993

Phi Beta Kappa: Elected Member, 1988

: President's Undergraduate Fellowship, 1988

U.C. Berkeley: President's Undergraduate Fellowship, 1988

Phi Beta Kappa: Elected Member, Junior year, 1988

Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA) BMC Res Notes. 2019 May 15; 12(1):275. . View in PubMed

Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens NPJ Breast Cancer. 2018; 4:32. . View in PubMed

mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer Cancer Lett. 2018 10 10; 434:152-159. . View in PubMed

Image-Based Tracking of Heterogeneous Single-Cell Phenotypes Methods Mol Biol. 2018; 1745:47-63. . View in PubMed

The emergence of dynamic phenotyping Cell Biol Toxicol. 2017 12; 33(6):507-509. . View in PubMed

Designing Successful Proteomics Experiments Methods Mol Biol. 2017; 1550:271-288. . View in PubMed

Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS) Sci Rep. 2016 Mar 03; 6:22435. . View in PubMed

Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma Genome Med. 2016 05 04; 8(1):54. . View in PubMed

Single cell dynamic phenotyping Sci Rep. 2016 10 06; 6:34785. . View in PubMed

Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype Prostate. 2013 Feb 15; 73(3):306-15. . View in PubMed

A cross-platform toolkit for mass spectrometry and proteomics Nat Biotechnol. 2012 Oct; 30(10):918-20. . View in PubMed

Naphthenic acids as indicators of crude oil biodegradation in soil, based on semi-quantitative electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry Rapid Commun Mass Spectrom. 2008 Dec; 22(23):3968-76. . View in PubMed

IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions J Neuroimmunol. 2008 Mar; 195(1-2):116-20. . View in PubMed

The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition Neoplasia. 2007 Jul; 9(7):601-13. . View in PubMed

Translation-invariant orientation tuning in visual "complex" cells could derive from intradendritic computations J Neurosci. 1998 Jun 01; 18(11):4325-34. . View in PubMed

Powered by SC CTSI
Go to Top